TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: GRam Stain-guided Antibiotics ChoicE for Ventilator-Associated Pneumonia (GRACE-VAP) Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing mechanical ventilation in the ICU~* Patients undergoing mechanical ventilation for at least 48 hours~* Patients diagnosed as having VAP, which is defined by a modified clinical pulmonary infection score of 5 or more~Exclusion Criteria:~* Patients having an allergy to study medications~* Pregnant patients~* Patients discharged from ICU~* Patients diagnosed as having heart failure or atelectasis~* Patients administered antibiotics for more than 24 hours when they meet the inclusion criteria~* Patients declined to provide full life support~* Patients judged as inappropriate at the discretion of the study physician.

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Gram stain-guided therapy group (Type: ACTIVE_COMPARATOR): The results of Gram staining of endotracheal aspirate are used to guide the selection of antibiotics. The results of the Gram stains are categorised as Gram-positive cocci (GPC) chains, GPC clusters, Gram-positive bacilli (GPB), Gram-negative rods (GNR), or a combination of these. A non-pseudomonal beta-lactam antibiotic is selected when the Gram stain of the endotracheal aspirate shows only GPC chains and/or GPB. An anti-MRSA agent is selected when the Gram stain results show GPC clusters without GNR. An anti-pseudomonal agent is selected when the Gram stain results show GNR without GPC clusters. The combination of an anti-pseudomonal agent and an anti-MRSA agent is selected when the Gram stain results show both GPC clusters and GNR.
- Guidelines-based therapy group (Type: ACTIVE_COMPARATOR): Patients are administered the combination of an anti-pseudomonal agent and anti-MRSA agent according to the Infectious Disease Society of America and the American Thoracic Society (IDSA/ATS) guidelines because 47.7% of S. aureus isolates are MRSA in Japanese ICUs

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: TMC207-C202: Study to Evaluate Bactericidal Activity of Multiple Oral Doses of TMC207 in Subjects With Sputum-Smear Positive Tuberculosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Treatment-naive subjects with pulmonary M. tuberculosis infection, willing to start anti-TB therapy~* Positive for acid-fast bacilli on direct smear exam of sputum specimen~* Must consent to HIV testing~* Must agree to hospital admission~Exclusion Criteria:~* History or presence of hepatic or GI disease that may interfere with the absorption of TMC207, isoniazid or rifampin~* Subjects who received previous anti-mycobacterial drugs for the treatment of a mycobacteria infection and subjects who have received more than 2 weeks of treatment with a fluoroquinolone~* Subjects who have received antiretroviral therapy and/or oral or I.V. anti-fungal medication w/in the last 90 days~* Subjects with sputum cultures of M. tuberculosis resistant to rifampin~* Impaired hepatic function

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Biological Therapy After Chemotherapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Immunohistopathologically documented relapsed or refractory CD20+ indolent lymphomas or mantle cell lymphoma~  * Indolent B-cell lymphomas including any of the following subtypes:~    * Follicular lymphoma (grade I, II, or III)~   * Small lymphocytic lymphoma or chronic lymphocytic leukemia~   * Marginal zone lymphoma (splenic, nodal, and extra-nodal)~   * Lymphoplasmacytoid lymphoma~* Ineligible for or unwilling to participate in other FHCRC/UWMC protocols~* Serological evidence of prior exposure to Epstein-Barr virus~* Must agree to undergo peripheral blood drawing, bone marrow biopsy, lymph node biopsy, and nuclear medicine imaging~* Must agree to cytoreductive chemotherapy if necessary to reduce lymph nodes to \< 5 cm in diameter or circulating B lymphocyte counts to \< 5,000/mm\^3~* No pulmonary involvement~* No CNS involvement~PATIENT CHARACTERISTICS:~Age:~* Any age~Performance status:~* Not specified~Life expectancy:~* At least 90 days~Hematopoietic:~* Not specified~Hepatic:~* No active hepatitis B infection~Renal:~* Not specified~Other:~* No HIV positivity~* Not pregnant or nursing~* Fertile patients must use effective contraception~* No history of hypersensitivity reactions to murine proteins~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* At least 4 months since prior rituximab, tositumomab, or ibritumomab~* No prior allogeneic stem cell transplantation~* No other concurrent immunotherapy (e.g., interferons, vaccines, or other cellular products)~Chemotherapy:~* At least 2 years since prior fludarabine or cladribine~* At least 4 weeks since prior chemotherapy and recovered~Endocrine therapy:~* No concurrent systemic corticosteroids except to treat toxicity from chemotherapy or cellular immunotherapy~Radiotherapy:~* Not specified~Surgery:~* Not specified~Other:~* At least 4 weeks since prior immunosuppressive therapy and recovered~* No concurrent pentoxifylline~* No other concurrent investigational agents

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Empagliflozin in Renal Transplant Recipients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Renal transplant recipient transplanted more than 1 year ago~* Stable renal function (\<20% deviation in serum creatinine within last 2 months)~* Stable immunosuppressive therapy ≥3 months before inclusion~* Diagnosed with PTDM:~(fasting plasma glucose ≥7.0 mmol/l and/or 2-hour plasma glucose ≥11.1 mmol/l following an oral glucose tolerance test)~-Signed informed consent and expected cooperation of the patients~Exclusion Criteria:~* Estimated GFR \<30 ml/min/1.73 m2~* Pregnant or nursing mothers~* Hypersensitivity to the active substance (IMP) or to any of the excipients~* Any reason why, in the opinion of the investigator, the patient should not participate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Empagliflozin (Type: ACTIVE_COMPARATOR): 10 mg once daily for 24 weeks
- Placebo (Type: PLACEBO_COMPARATOR): 1 capsule once daily for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Deep Neuromuscular Block on Surgical Conditions in Morbidly Obese Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ASA I-III~* BMI \> 34 kg/m2~* Elective bariatric surgery.~Exclusion Criteria:~* Known or suspected neuromuscular disorders impairing neuromuscular function~* Allergies to muscle relaxants, anesthetics or narcotics~* A(family) history of malignant hyperthermia~* Women who are or may be pregnant or are currently breast feeding~* Renal insufficiency, as defined by serum creatinine x 2 of normal, or urine output \< 0.5 ml/kg/h for at least 6 h.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- moderate neuromuscular block (Type: ACTIVE_COMPARATOR): rocuronium 0.1-0.6 mg/kg aimed at a train of four of 1 - 2 twitches
- deep neuromuscular block (Type: EXPERIMENTAL): rocuronium 0.1-0.6 mg/kg aimed at a post tetanic count of 1 - 2 twitches

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial~* T1DM (type 1 diabetes mellitus) (as diagnosed clinically) for not more than 20 weeks prior to screening - Male or female, aged 18-45 (both inclusive) at the time of signing the informed consent form~* Non-fasting peak C-peptide higher or equal to 0.2 nmol/l at visit 2~* BMI (body mass index) higher or equal to 18.5 kg/m\^2~* Presence of one or more islet specific auto antibodies (glutamic acid decarboxylase (GAD), islet antigen-2 (IA2) or zinc-transporter 8 (ZnT8)) at screening~* Insulin dependence unless in temporary spontaneous remission (honeymoon period)~Exclusion Criteria:~* Daily insulin usage above 1 U/kg per day at screening or use of continuous subcutaneous insulin infusion (CSII)~* History of recurrent (e.g. several times a year) of severe (e.g. pneumonia) or chronic infections or conditions predisposing to chronic infections (e.g., bronchiectasis and chronic osteomyelitis)~* History of severe systemic fungal infection within the past 12 months prior to screening unless treated and resolved with appropriate documented therapy~* Vaccination within 4 weeks before randomisation, Visit 3 (V3)~* Receipt of any other concomitant medications or herbal products that can influence the immune system within 90 days prior to screening (V1)~* History of pancreatitis (acute or chronic)~* Family or personal history of Multiple Endocrine Neoplasia Type 2 (MEN2) or Medullary Thyroid Carcinoma (MTC)~* Any past or current diagnosis of malignant neoplasms~* Known impairment of the immune system, except for T1DM, coeliac disease, alopecia, autoimmune antibodies not considered clinical important (e.g. thyroid antibodies without any clinically important thyroid disease), and vitiligo

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- NNC0114-0006 + Liraglutide (Type: EXPERIMENTAL): None
- NNC0114-0006 + Placebo (Type: EXPERIMENTAL): None
- Liraglutide + Placebo (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Haploidentical Donor Hematopoietic Progenitor Cell and NK Cell Transplantation for Hematologic Malignancy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria - Transplant Recipients:~* Age less than or equal to 21 years.~* Does not have a suitable MSD or volunteer MUD available in the necessary time for stem cell donation.~* Has a suitable single haplotype matched (≥ 3 of 6) and family member donor.~* High risk hematologic malignancy.~* If prior CNS leukemia, it must be treated and in CNS CR~* Does not have any other active malignancy other than the one for which this HCT is indicated.~* No prior allogeneic HCT, and no autologous HCT within the previous 12 months.~* Patient must fulfill pre-transplant evaluation~Inclusion Criteria - Haploidentical Donor:~* At least single haplotype matched (≥ 3 of 6) family member~* At least 18 years of age.~* HIV negative.~* Not pregnant as confirmed by negative serum or urine pregnancy test within 14 days prior to enrollment (if female).~* Not breast feeding.~* Regarding eligibility, is identified as either: (1) Completed the process of donor eligibility determination as outlined in 21 CFR 1271 and agency guidance; OR (2) Does not meet 21 CFR 1271 eligibility requirements, but has a declaration of urgent medical need completed by the principal investigator or physician sub-investigator per 21 CFR 1271.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Transplant Recipients (Type: EXPERIMENTAL): Participants undergo a preparative regimen of total lymphoid irradiation, fludarabine, cyclophosphamide, fludarabine, thiotepa, melphalan, and mycophenolate mofetil, followed by HPC,A infusion and TC-NK infusion. They also receive G-CSF and mesna.~Cells for infusion are prepared using the CliniMACS System.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic Syndrome (MDS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. MDS and 5% or more marrow blasts, or IPSS risk intermediate 1-2 or high risk; or chronic myelomonocytic leukemia~2. Performance status 0-2 (Eastern Cooperative Oncology Group (ECOG) scale); adequate hepatic (bilirubin \< 2 mg/dl) and renal functions (creatinine \<2mg/dl); New York Heart Association (NYHA) cardiac status III-IV excluded.~3. Signed informed consent~4. No prior intensive combination chemotherapy or high-dose ara-C (\>/= 1g/m2 per dose). Prior biologic therapies, targeted therapies and single agent chemotherapy allowed.~5. Patients must have been off chemotherapy for 2 weeks prior to entering this study and recovered from the toxic effects of that therapy, unless there is evidence of rapidly progressive disease. Use of Hydroxyurea for patients with rapidly proliferative disease is allowed for the first two weeks on therapy.~Exclusion Criteria:~1. Nursing and pregnant females are excluded. Patients of childbearing potential should practice effective methods of contraception. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.~2. Patients with active and uncontrolled infections~3. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or psychiatric illness/social situations that would limit compliance with study requirements

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Decitabine 10 mg/m^2 IV (Type: ACTIVE_COMPARATOR): 10 mg/m\^2 intravenous (IV) over 1 hour daily for 10 days
- Decitabine 20 mg/m2 IV (Type: ACTIVE_COMPARATOR): 20 mg/m2 IV over 1 hour daily for 5 days
- Decitabine 20 mg/m2 SQ (Type: ACTIVE_COMPARATOR): 20 mg/m2 subcutaneous (SQ) daily for 5 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Kappa-PET Imaging and Naltrexone in Alcohol Drinking Behaviors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Ages 21-50~* Able to read English at 6th grade level or higher and to complete study evaluations~* Regular alcohol drinker~Exclusion Criteria:~* Individuals who are seeking alcohol treatment~* Medical conditions that would contraindicate the use of study medication~* Regular use of other substances

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Naltrexone (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Contractubex Treatment in Scars After Abdominal Caesarean Section

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Females having given birth via elective abdominal Caesarean section for the first time within the last 5 to 10 days who had their suture removed (removed at screening).~* Age: 18 years or older.~* The subject must be willing and must be able to complete the entire course of the trial and to comply with the trial instructions.~* Written informed consent has been obtained from the subject.~* Females using suitable contraceptions.~Exclusion Criteria:~* Use of any inadmissible medication, e.g. systemic corticosteroids, systemic immunosuppressants (such as cytostatics, therapy with antibodies, biologics, interferone, mykophenolatmofetil, methotrexate, cyclosporine, azathioprine). Any additional topical treatment in the area of the lower abdomen, regardless of the mode of action.~* Any other planned topical treatment in the lower part of the abdomen during the course of the trial.~* Any infection or wound in the area to treat.~* History of keloids or hypertrophic scars.~* Any severe or uncontrolled systemic disease (e.g. cardiac, renal, pulmonary, hepatic, or gastrointestinal), malignant tumor, or medical history of HIV infection.~* Any tumor diseases in the abdominal region independent of their dignity.~* Females having given birth via emergency abdominal Caesarean section.~* Psychiatric problems which, in the investigator's opinion, are severe enough to interfere with the trial results.~* Participation in another clinical trial within 30 days prior to screening.~* Evidence or suspicion that the subject might not comply with the study directives and/or that she is not reliable or trustworthy.~* Evidence or suspicion that the subject is not willing or unable to understand the information given to her as part of the informed consent, in particular regarding the risks and discomfort to which she would agree to be exposed.~* Previous participation in this clinical study.~* Known allergy or hypersensitivity to the study drug(s) or one of the ingredients of the formulation.~* Subjects who are imprisoned or are lawfully kept in an institution.~* Employees or direct relatives of an employee of the CRO, the study center or Merz Pharmaceuticals.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Contractubex (Type: EXPERIMENTAL): None
- Non treatment (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: CAVATAK (CVA21) in Non-muscle Invasive Bladder Cancer (VLA-012 CANON)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of NMIBC based on cystoscopic appearance~* ECOG 0-2~* No intravesical therapy within 6 weeks of study entry~* No prior radiation to the pelvis~* ANC \>1500/mm³; Hb \>9.0 g/dL; Platelet \>100000/mm³~* Serum creatinine ≤ 1.5 mg/dL~* Bilirubin within normal limits; AST ≤ 2.5x upper limit of normal (ULN); ALT ≤ 2.5 x ULN; alkaline phosphatase ≤ 2.5x ULN unless bone metastasis is present in the absence of liver metastasis~* INR \< 1.2; aPPT = 0.8-1.2; PT = 0.9-1.8~* Candidate for TUR and planning to undergo TUR~* Negative pregnancy test within 7 days of treatment start~* Patients of child-bearing potential must agree to use an effective method of birth control~Exclusion Criteria:~* Prior local or systemic treatments for NMIBC~* Concurrent treatment with any chemotherapeutic agent~* Patients not deemed acceptable for general anaesthesia~* Women who are pregnant or lactating~* History of vesicoureteric reflux or an indwelling urinary stent~* Administration of an investigational agent within 3 months of study entry~* Active cardiac disease~* Known infection with HIV, hepatitis B or C~* Active uncontrolled infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CVA21 (Type: EXPERIMENTAL): CVA21 was administered by intravesical instillation at one of three (3) ascending dose levels or schedules.
- CVA21/Mitomycin C (Type: EXPERIMENTAL): Mitomycin C (MMC) was administered at 10 mg by intravesical instillation on Day 1. Four hours after instillation of MMC, CVA21 was administered by intravesical instillation of one of 2 ascending dose levels or schedules. Subjects received a second instillation of CVA21 alone on Day 2 without pretreatment with MMC.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Dose Ranging Study Comparing Different Combinations of Adjuvanted and Non-adjuvanted Influenza Vaccines in Healthy Children 6 to <36 Months of Age

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Children of 6 month to \<36 month of age in good health as determined by medical history, physical assessment and clinical judgement of the investigator.~Exclusion Criteria:~* History of serious disease. History of serious reaction following administration of vaccine or hypersensitivity to vaccine components. Known or suspected impairment/alteration of immune function.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 35 Months
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete